← Companies|BigHat Bio
Bi

BigHat Bio

San Mateo CAFounded 201940 employees
Private CapbiotechPrivateOncology
Platform: ML Ab Design
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
ZanutuximabBIG-8335Phase 21NanobodyTYK2CDK4/6iGBMWilms
BIG-7200BIG-7200Phase 12Cell TherapyKRASG12DPD-1iASMigraine
MavucageneBIG-2789NDA/BLA2MultispecificJAK2PARPiCLL
BIG-3814BIG-3814Approved3mAbWRNGLP-1agHemophilia A
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (7)
2025-12-01
BIG-7200 Interim
Migraine
Past
2026-01-13
Zanutuximab PDUFA
Wilms
Past
2026-07-27
BIG-3814 Ph3 Readout
Hemophilia A
Ph3 Readout
2027-11-27
BIG-3814 Ph3 Readout
Hemophilia A
Ph3 Readout
2028-12-01
BIG-3814 Ph3 Readout
Hemophilia A
Ph3 Readout
2031-02-04
Mavucagene Ph3 Readout
CLL
Ph3 Readout
2031-09-05
BIG-7200 Interim
Migraine
Interim